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INTRODUCTION: PXR polymorphisms have been implicated in modulating CYP3A4 and PXR expression, potentially
accounting for interindividual differences in drug metabolism. The prevalence of PXR polymorphisms varies among
ethnic groups and data on the allelic distribution in the highly mixed Brazilian population is lacking. The aim of this
study was to analyze genetic variations in the PXR gene in Brazilians and to compare the results to other ethnic
groups.
METHODS: DNA samples from 117 healthy Brazilians underwent PCR amplification and sequencing.
RESULTS: Eleven polymorphisms were identified, 3 of which are highly associated with differences in CYP3A4 expression.
We also identified 1 new synonymous variant in 1.3% of the alleles. Among the functional polymorphisms, –25913 C.T
and –6994T.C occurred at a higher frequency compared to the African alleles (p , 0.05) but at a lower frequency
compared to Caucasian alleles. The 8055 C.T allele was found at a similar frequency to those described in Caucasians and
Africans (p . 0.05).
CONCLUSION: We observed that functional variants of the PXR were frequent in our sample of
the Brazilian population. Our results suggest that PXR gene variants may be of interest in pharmacogenetic
studies involving Brazilians.
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INTRODUCTION
The interindividual variability in human drug metabo-
lism may be genetically determined by allelic variance in
genes encoding P450 proteins and nuclear receptors.1-4
Cytochrome P450s metabolize approximately 80% of clinical
drugs and polymorphisms in the CYP3A4 gene have been
previously investigated due to its involvement in the
metabolism of more than 50% of drugs. Despite the large
interindividual differences in CYP3A4 expression, poly-
morphisms that impair enzyme activity seem to be rare.5-7
CYP3A4 expression is mainly induced by the pregnane X
receptor (PXR),8-10 a member of the orphan nuclear receptor
subfamily and the main transcriptional regulator of cyto-
chrome P4503A enzymes.8,9 The activation of PXR initiates
in the cytoplasm. After exposure to ligands, PXR dimerizes
with the retinoic acid receptor (RXR) and binds to nuclear
receptor response elements in the upstream regulatory
regions of target genes. These genes encode drug-metabo-
lizing enzymes such as CYP3A4 and drug transporters,11
which are the main regulators in the uptake and transfor-
mation of many prescribed medicines.
Several PXR (also known as NR1I2) polymorphisms have
been identified that influence the level of PXR expression and,
therefore, indirectly regulate its target genes.4,12 These poly-
morphisms account for the wide variability of CYP3A4 levels in
the population.4,13 The functional effects of these polymorph-
isms include aberrant DNA binding and alterations in the
transactivation and expression of downstream target genes.4,12
While the allelic distribution of the PXR gene varies
widely among different ethnic groups,13-17 it has yet to be
studied in the highly mixed Brazilian population. Here we
analyze the frequency of PXR variants in a sample of
healthy Brazilian subjects. We also compare the frequencies
of PXR polymorphisms to those described in Asians,
Caucasians, and Africans in order to determine whether
PXR variants should be evaluated in pharmacogenetic
studies involving Brazilian subjects.
Subjects
The study protocol was approved by the Ethical
Committee of Sa˜o Paulo University. Written consent was
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obtained from all subjects. Healthy volunteers consisted of
76 females and 41 males with a mean age 25.8¡ 11.8 years.
The self-reported ethnicity of this cohort was 87.2%
Caucasian and 12.8% African. In addition, 88% were from
the southeast, 8.5% from the northeast, and 3.5% from the
southern region of Brazil.
METHODS
DNA samples from all subjects were obtained from
peripheral blood leukocytes using a salting out procedure.
All coding regions of the PXR gene were analyzed in addition
to three variants in non-coding regions that had aminor allele
frequency of at least $ 0.10 in other ethnic groups. We also
looked for three variants, which modified the PXR and/or
CYP3A4 expression, previously described in non-coding
regions with a minor allele frequency $ 0.10 in other ethnic
groups.4,17 The PXR gene was amplified as previously
described.4,18 The amplified products were sequenced using
the Big Dye Terminator Sequencing KitTM (Applied
Biosystem, Inc., Foster City, CA, USA) and capillary electro-
phoresis was conducted on an ABI PRISM 3100 sequencer
(Applied Biosystem, Inc.). Sequence traces were analyzed
using Sequencher (version 4.5 build 1416) and assembled to
the reference (NCBI accession number AF364606).
Statistical Analysis
When appropriate, identified allele frequencies were
compared to the expected normal distribution in a popula-
tion (Hardy-Weinberg equilibrium) by using a goodness-of-
fit x2 test.
Differences in allele frequencies between ethnic groups
were analyzed using the x2 test. Values of p , 0.05 were
considered to be significant.
RESULTS
The allelic frequencies of PXR polymorphisms that we
identified in this study are shown in Table 1 along with
previously published data fromAsian, Caucasian, andAfrican
populations. The genotypic frequencies that we found are
listed in Table 2. All polymorphisms were in Hardy-Weinberg
equilibrium.We identified 11 polymorphisms (Tables 1 and 2),
one of which is a new synonymous variant located in exon 4
(4306 C.G) that was present in 1.3 % of Brazilian alleles. Eight
polymorphisms were identified in the coding regions of the
PXR gene and 3 polymorphisms in non-coding regions. Of the
variants identified, 8055 C.T, -25913 C.T, and -6994 C.T are
known to be associated with functionality.
The 8055 C.T (rs2276707) variant was found in 12.5% of
alleles, which is similar to its frequencies in Caucasian and
African alleles of 15% and 18% (p. 0.05),12 respectively, but
lower than its frequency in Chinese alleles of 45% (p ,
0.05).19 The -25913 C.T (rs1523130) variant occurred in 50%
of the Brazilian alleles, which is less frequent than in
Caucasians (70%, p = 0.003, 95% CI: 0.66-0.76) but more
frequent than in Africans (28%, p, 0.001, 95% CI: 0.49-0.61).
The -6994 C.T (rs2472677) polymorphism was found in
46% of the Brazilian alleles, which is a higher frequency
than in Africans (38.1%, p = 0.03, 95% CI: 0.80-0.85) but a
lower frequency than in Caucasians (62%, p = 0.01, 95% CI:
0.70-0.79).
The 79 C.T (rs12727613) polymorphism was found in
2.1% of Brazilian alleles. This variant is significantly more
frequent in African alleles (20%, p , 0.001) and not present
in Caucasians or Asians. The 106 G.A (rs12721607)
polymorphism, which is absent in Asians, was found in
1.3% of alleles in this population, similar to its frequencies in
Caucasians and Africans of 5% and 4%, respectively (p ,
0.05). The 4321 G.A (rs12721608) polymorphism is absent
in Africans but present in Brazilians at a similarly low
frequency as that found in Caucasians (p , 0.05). The other
five polymorphisms were detected at a frequency lower
than 1% [4447 T.C (rs12721611), 4499 C.T (rs12721600),
4773 G.A (rs12721612), and 8528 G.A (rs59152710)].
DISCUSSION
PXR polymorphisms have been implicated in modulating
CYP3A4 and PXR expression, potentially accounting for
interindividual differences in drug metabolism.20 These
variants impact drug response and some types of drug
interactions by affecting serum levels of the medicines and
endogenous compounds, which can include PXR ligands
and substrates of enzymes and drug transporters.13 The
distribution of allelic variants in the PXR gene varies widely
among different ethnic groups,12,14 which helps to explain
variations in the pharmacokinetics and pharmacodynamics
of drugs that are PXR ligands.
Table 1 - Allelic frequency of polymorphisms in the PXR gene in Brazilians compared to Asians, Caucasians, and Africans.
Location dbSNP
*Position in
AF364606
Amino Acid
Change Asians Caucasians Africansa This study
n˚ Frequency n˚ Frequency n˚ Frequency n˚ Frequency
59UTR rs1523130 -25913 C.T - 801 0.67 801 0.70 801 0.28 234 0.50
Intron 1 rs2472677 -6994 C.T - 924 0.62 714# 0.381 234 0.457
Exon 2 rs12727613 79 C.T Pro27Ser 801 0 3002 0 663 0.20 234 0.021
Exon 2 rs12721607 106 G.A Gly36Arg 801 0 801 0.05 801 0.04 234 0.013
Exon 4 - 4306 C.G Arg156Arg 234 0.013
Exon 4 rs12721608 4321 G.A Gln122Arg 1443 0.01 714# 0 234 0.012
Exon 4 rs12721611 4447 T.C Thr164Thr 801 0 801 0 801 0.03 234 0.008
Exon 5 rs12721600 4499 C.T Gly220Gly 234 0.008
Exon 6 rs12721612 4773 G.A Gly317Gly 234 0.004
Intron 6 rs2276707 8055 C.T - 801 0.51 1505 0.15 225 0.18 234 0.125
Exon 8 rs59152710 8528 G.A Ala370Thr 3122 0 642 0.016 234 0.004
aAfrican-American population. n˚: number of alleles. Data from Asians, Caucasians, and Africans was obtained from
1King et al. 2007, 2Hustert et al. 2001,
3Wang et al. 2008, 4Lamba et al. 2008, and 5Zhang et al. 2008. #Data from sub-Saharan Africans (Svard et al. 2010). Italics: new variant. *Position in
relation to translation start site of PXR (NR1I2): GenBank Accession AF364606.
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This study was carried out in order to determine the
frequency of variants of the PXR gene in a sample of the
Brazilian population. We found 11 polymorphisms in the
PXR gene, including the 4306 C.G substitution in exon 4
that has not been previously described. This variant is not
predicted to alter the splice site in exon 4 of the PXR gene
and is unlikely to alter protein function.
The Brazilian population is highly heterogeneous, result-
ing from centuries of interbreeding among peoples from
three continents: European colonizers (mostly Portuguese),
African slaves, and native Indians.21 Although Brazilians
contain approximately 28% of African alleles, we found that
the variant C79T (rs12727613), which occurs in 20% of alleles
Africans, occurred at a much lower than expected frequency
in our sample (2.1%). On the other hand, the –25913 C.T
(rs1523130) polymorphism that is present in 28% of African
alleles was present at a significantly higher frequency in our
population (50%, p = 0.003). We also found that the -
6994T.C (rs2472677), which is present in 38% of African
alleles, was significantly more frequent in the Brazilian
alleles (46%, p = 0.03). Finally, the –25913 C.T and –
6994T.C polymorphisms were not as frequent in the
Brazilian alleles as in Caucasian alleles (p , 0.05).
Our results are distinctly clustered. This could represent
the unique admixture of the regional subpopulation from
the southeast region of Brazil, which has similar ancestral
contributions from African (34%), European (31%), and
Native American (33%) alleles, in contrast to the higher
proportion of African lineages observed in the northeast
region.21-23
Our study emphasizes the population-dependent fre-
quency of PXR polymorphisms. The polymorphism fre-
quencies found in our sample differ greatly from those
previously described in Caucasians and Africans. Our
results suggest that variants in the PXR gene should be
considered in pharmacogenetic studies involving Brazilians
from the southeast region, since the miscegenation varies
from region to region.
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